Dianthus Therapeutics (DNTH) Retained Earnings: 2017-2025
Historic Retained Earnings for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to -$272.3 million.
- Dianthus Therapeutics' Retained Earnings fell 86.51% to -$272.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$272.3 million, marking a year-over-year decrease of 86.51%. This contributed to the annual value of -$174.4 million for FY2024, which is 95.02% down from last year.
- According to the latest figures from Q3 2025, Dianthus Therapeutics' Retained Earnings is -$272.3 million, which was down 15.61% from -$235.5 million recorded in Q2 2025.
- Dianthus Therapeutics' 5-year Retained Earnings high stood at -$45.9 million for Q4 2022, and its period low was -$434.5 million during Q2 2023.
- For the 3-year period, Dianthus Therapeutics' Retained Earnings averaged around -$208.2 million, with its median value being -$174.4 million (2024).
- As far as peak fluctuations go, Dianthus Therapeutics' Retained Earnings surged by 76.07% in 2024, and later slumped by 97.58% in 2025.
- Over the past 4 years, Dianthus Therapeutics' Retained Earnings (Quarterly) stood at -$45.9 million in 2022, then crashed by 94.96% to -$89.4 million in 2023, then plummeted by 95.02% to -$174.4 million in 2024, then crashed by 86.51% to -$272.3 million in 2025.
- Its last three reported values are -$272.3 million in Q3 2025, -$235.5 million for Q2 2025, and -$203.9 million during Q1 2025.